Cipla | CIPLA - Gross Profit On Sales


Cipla reported INR39.1B in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
Arca Biopharma 0 0 Mar/2025
aTyr Pharma USD 190K 15.57M Sep/2025
Capricor Therapeutics 11.13M 8.87M Dec/2024
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Cipla INR 39.1B 2.54B Mar/2026
Dr.Reddys Laboratories INR 37.77B 13.6B Mar/2026
Esperion Therapeutics USD 140.59M 94.57M Dec/2025
Immunic 0 0 Mar/2025
Minerva Neurosciences -4.27M 26.79M Dec/2024
Nektar Therapeutics USD 21.81M 8.06M Dec/2025
Sangamo BioSciences -2.39M 1.09M Jun/2024
Sun Pharmaceuticals INR 125.24B 17.58B Dec/2025
TherapeuticsMD USD 234K 79K Jun/2024
UPL INR 55.96B 1.01B Dec/2025